CU20110130A7 - Uso de racematos de pinocembrin en la preparación de medicamentos para tratar isquemia - Google Patents

Uso de racematos de pinocembrin en la preparación de medicamentos para tratar isquemia

Info

Publication number
CU20110130A7
CU20110130A7 CU20110130A CU20110130A CU20110130A7 CU 20110130 A7 CU20110130 A7 CU 20110130A7 CU 20110130 A CU20110130 A CU 20110130A CU 20110130 A CU20110130 A CU 20110130A CU 20110130 A7 CU20110130 A7 CU 20110130A7
Authority
CU
Cuba
Prior art keywords
pinocembrin
racemates
medicines
preparation
treat ischemia
Prior art date
Application number
CU20110130A
Other languages
English (en)
Inventor
Xiaolong Feng
Rui Liu
Haili Liu
Yingui Li
Ying Shi
Hongmei Guang
Yan Qi
Mei Gao
Guanhua Du
Song Wu
Dongmin Shen
Jinxu Wang
Original Assignee
Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Inst Materia Medica Cams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd, Inst Materia Medica Cams filed Critical Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CU20110130A7 publication Critical patent/CU20110130A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Uso de un racemato de pinocembrina, una sal de racenato de pinocembrina, un precursor del racemato de pinocembrina o un hidrato de racemato de pinocembrina en fabricación de un medicamento para profilaxis y tratamiento de la apoplejía. Particularmente, uso de racemato de pinocembrina en la fabricación de un medicamento para el tratamiento de la apoplejía isquémica aguda.
CU20110130A 2008-12-11 2011-06-09 Uso de racematos de pinocembrin en la preparación de medicamentos para tratar isquemia CU20110130A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200810185559 2008-12-11

Publications (1)

Publication Number Publication Date
CU20110130A7 true CU20110130A7 (es) 2012-01-31

Family

ID=42242358

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110130A CU20110130A7 (es) 2008-12-11 2011-06-09 Uso de racematos de pinocembrin en la preparación de medicamentos para tratar isquemia

Country Status (17)

Country Link
US (1) US20110245334A1 (es)
EP (1) EP2377529A4 (es)
JP (1) JP5770098B2 (es)
KR (1) KR20110094136A (es)
CN (1) CN102548626A (es)
AP (1) AP2011005766A0 (es)
AU (1) AU2009326715B2 (es)
BR (1) BRPI0923242A8 (es)
CA (1) CA2746457A1 (es)
CU (1) CU20110130A7 (es)
EA (1) EA022275B1 (es)
IL (1) IL213440A0 (es)
MX (1) MX2011006141A (es)
SG (1) SG172072A1 (es)
UA (1) UA102874C2 (es)
WO (1) WO2010066199A1 (es)
ZA (1) ZA201105037B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant
UY26816A1 (es) * 2001-07-04 2003-04-30 Horacio Heinzen Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo.
CN1285334C (zh) * 2004-05-12 2006-11-22 中国医学科学院药物研究所 生松素在制备防治神经细胞损伤相关疾病药物中的应用
CN1879656B (zh) * 2006-04-27 2010-04-21 魏春华 固体水溶性蜂胶组合物及其制备方法
CN101537188B (zh) * 2007-03-21 2012-07-18 中国医学科学院药物研究所 松属素环糊精或环糊精衍生物包合物
CN101307044B (zh) * 2007-05-16 2012-07-04 中国医学科学院药物研究所 生松素化合物两种晶型和制备方法及在疾病治疗中的应用
US20090232782A1 (en) * 2008-03-14 2009-09-17 Yu-Show Fu Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells
AP2011005707A0 (en) * 2008-11-11 2011-06-30 Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.

Also Published As

Publication number Publication date
EP2377529A1 (en) 2011-10-19
WO2010066199A1 (zh) 2010-06-17
EA201170776A1 (ru) 2011-12-30
EA022275B1 (ru) 2015-12-30
UA102874C2 (uk) 2013-08-27
AU2009326715B2 (en) 2015-12-03
CA2746457A1 (en) 2010-06-17
US20110245334A1 (en) 2011-10-06
EP2377529A4 (en) 2013-05-22
KR20110094136A (ko) 2011-08-19
JP2012511518A (ja) 2012-05-24
BRPI0923242A2 (pt) 2016-01-26
SG172072A1 (en) 2011-07-28
AP2011005766A0 (en) 2011-06-30
BRPI0923242A8 (pt) 2016-09-13
JP5770098B2 (ja) 2015-08-26
AU2009326715A1 (en) 2011-07-14
MX2011006141A (es) 2011-09-21
ZA201105037B (en) 2012-09-26
IL213440A0 (en) 2011-07-31
CN102548626A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
TWD161529S (zh) 治療燈
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
RS52102B (en) PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CL2013003230A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos.
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
PH12016501096A1 (en) SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
CL2011001817A1 (es) Forma de dosificacion unitaria solida oral en forma de tableta que comprende un nucleo y un recubrimiento externo, en donde el nucleo comprende alisquireno o a una sal del mismo, y el recubrimiento en un recubrimiento de pelicula, util para el tratamiento de una enfermedad o condicion en una poblacion pediatrica.
CU20110130A7 (es) Uso de racematos de pinocembrin en la preparación de medicamentos para tratar isquemia
CL2016000583A1 (es) Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica.
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
CL2015000848A1 (es) Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12).
CL2008000607A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y nalmefeno, util para el tratamiento del dolor.
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos